Related Experiment Videos

Histological changes in cardiac hemochromatosis improved by an iron-chelating agent. A biopsy case

A Tashiro1, R Satodate, I Segawa

  • 1Department of Pathology II, Iwate Medical University School of Medicine, Morioka, Japan.

Acta Pathologica Japonica
|April 1, 1990
PubMed

Insights

Deferoxamine mesylate improved cardiac dysfunction in a patient with secondary hemochromatosis. Iron chelation therapy reduced hemosiderin in heart muscle, but liver iron remained.

Area of Science:

  • Cardiology
  • Hematology
  • Pathology

Background:

  • Secondary hemochromatosis can cause cardiac dysfunction and ECG abnormalities.
  • Sideroblastic anemia is a potential underlying condition associated with iron overload.

Observation:

  • A 51-year-old woman presented with cardiac dysfunction and ECG abnormalities.
  • Endomyocardial biopsy revealed hemosiderin deposition in myocytes, causing vacuolization and disarray.

Findings:

  • Treatment with deferoxamine mesylate, an iron-chelating agent, led to clinical improvement.
  • Repeat endomyocardial biopsy showed reduced hemosiderin, improved myocyte vacuolization, and disarray.
  • Ultrastructural analysis and X-ray microanalysis confirmed decreased iron granules within myocytes.

Implications:

  • Deferoxamine mesylate is effective in treating cardiac siderosis secondary to hemochromatosis.
  • While cardiac iron can be reduced, persistent liver iron deposition requires further monitoring.
  • This case highlights the importance of evaluating cardiac function in patients with iron overload disorders.

Related Concept Videos